REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by, and welcome to Regenexx BIO's fourth quarter and year-end 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. To remove yourself from the queue, you may press star 11 again. I would now like to hand the call over to Patrick Christmas, Chief Legal Officer of Regenexx Bio. Please go ahead. Good morning, and thank you for joining us today. Earlier this morning, Regenexx Bio released financial and operating results for the fourth quarter and year ending December 31, 2025. The press release is available on our website at www.regenexxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management's Discussion and Analysis section of Regenexx BIO's annual report on Form 10-K for the full year ended December 31, 2025, and Comparable Risk Factors section of Regenexx BIO's quarterly reports on Form 10-Q, which will be on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, March 5...